Tuesday, August 29, 2017

Postdoctoral opportunity at NCTR in Arkansas

I received the following in an email this morning. 

A fellowship research opportunity is expected to become available in the Division of Biochemical Toxicology (DBT), National Center for Toxicological Research (NCTR), Food and Drug Administration (FDA) in the fall of 2017.

The primary objective of this project is to construct an integrated computational tool, which consists of databases, referenced literatures, and a multi-pathway physiologically based pharmacokinetic (PBPK) model for tobacco components, to assist FDA Center for Tobacco Products make science-based regulatory decisions for reducing the abuse liability and adverse public health impact from tobacco products in humans.

This program, administered by ORAU through its contract with the U.S. Department of Energy (DOE) to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA/NCTR at Jefferson, AR.  Participants do not become employees of FDA or the program administrator, and there are no fringe benefits paid.


·         A Doctoral Degree in biological sciences, toxicology, pharmacology, pharmacometrics, pharmaceutical sciences, computational biology/bioinformatics, biomedical engineering or related fields.

·         Must have the interest and desire to learn the development and application of computational modeling for risk assessment.

·         Hands-on experience with computational modeling and simulation as well as knowledge of pharmacokinetics and toxicological principles is preferred.

·         Experience with software to characterize the deposition and clearance of aerosols in the respiratory tracts for inhalation exposure, such as Multiple Path Particle Dosimetry Model (MPPD), is a strong plus.

How To Apply

If you are interested, please send your current resume/CV to Drs. Xiaoxia Yang (Xiaoxia.Yang@fda.hhs.gov) or Jeffrey Fisher (Jeffrey.Fisher@fda.hhs.gov).

No comments: